Harness the power of AI and accelerate reporting in CAR-T research
ImmunoMind, which graduated from UC Berkeley SkyDeck, helps companies and medical centres design and produce safer and more effective CAR-T and other Cell Therapies, leveraging a proprietary multi-omics database of immune cells and AI. This collaboration connects eLabNext users to the ImmunoMind platform and enhances reporting in eLabJournal by using results from multi-omics driven drug development and manufacturing.
The ImmunoMind add-on identifies both cell subpopulations (e.g. Tscm, Tcm, Tem, Treg, NK, gdT cells) as well as their characteristics (e.g. exhaustion, senescence, activation) to create a comprehensive profile of CAR-T and other Cell Therapy products.
Bring forth the synergy between biologists, medical scientists, data scientists and bioinformaticians.
Understanding the extensive cell heterogeneity leads to safer CAR-T therapies
Transcriptomics driven selection of CAR-T candidates
Targeting the T-cell exhaustion to improve the efficacy of CAR-T therapy
Improving clinical trials with bulk RNA-sequencing
The ImmunoMind add-on is available free of charge in the eLab Marketplace.